ASX Linkedin Twitter               

 

Media Reports 2014

30 Sep 2014 Sky Business News Switzer
Viralytics identified by James Dunn of Dunn Media as one of four biotechs to watch in the current market – commencing at 6’00
View Video (external link)

2 Sep 2014 Channel 7 News Report “Brain Drain”
CAVATAKTM among several technologies featured – commencing at 2’35
View Video Courtesy of Channel 7

12 Jun 2014 Channel 7 News Report “Cold Comfort”
View Video Courtesy of Channel 7

2 Jun 2014 NBN News Report “Common cold cancer treatment”
View Video Courtesy of NBN

25 Mar 2014 ABC The Business Report “New Frontiers for Australia’s bio-tech industry”
View Video (external link)

4 Feb 2014 Herald Sun
Read Article (external link)

31 Jan 2014 Sky News Business Report “Transformational Capital Raising”
View Video Courtesy of Sky News

30 Jan 2014 Newcastle Herald
Read Article (external link)

30 Jan 2014 Daily Telegraph
Read Article (external link)

30 Jan 2014 The Australian
Read Article (external link)

 

Cancer Immunotherapy – Breakthrough Technology of the Year 2013

The American Association for the Advancement of Science has in its prestigious Science Journal, named Cancer immunotherapy as the Breakthrough Technology of 2013. The journal article, authored by Jennifer Couzin-Frankel, reported that several clinical trials in the field had served to completely change the landscape around treatment of cancer and to convert many previously skeptical observers.

Immunotherapy harnesses the body’s own immune systems against the cancers. Viralytics’ CAVATAKTM technology achieves this by using a targeted mechanism to disrupt cancer cells and stimulate an immune response. The Science report cited new generation PD-1 therapies as providing cause for optimism where none existed a few years previously but also acknowledged that immunotherapy as a whole had impacted only a handful of patients to date.
Read full article

 

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).